BFRA News and Press, Biofrontera AG

Biofrontera (BFRA -3.4%) announced that the company decided to delist its American Depositary Shares (ADS) from the Nasdaq Capital Market. Concurrently, its reporting requirements with the U.S. Securities and Exchange Commission (SEC) will also come to an end. The decision followed its plans ...

Leverkusen, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, decided today its American Depositary Shares (“ADS”) should be delisted from the N...

Gainers: Doximity (NYSE:DOCS) +20%. Aptevo Therapeutics (NASDAQ:APVO) +17%. Biofrontera (NASDAQ:BFRA) +14%. Karyopharm Therapeutics (NASDAQ:KPTI) +14%. Teva Pharmaceutical (NYSE:TEVA) +9%. Losers: Varex Imaging (NASDAQ:VREX) -11%. BioCardia (NASDAQ...

US Ecology ECOL +23% Republic Services is said in talks to purchase US Ecology. Enphase Energy ENPH +22% on Q4 results. ERYTECH Pharma (NASDAQ:ERYP) +13% expands patent portfolio for the treatment of rare metabolic diseases. Biofrontera (NASDAQ:BFRA) +12%. AVROBIO (NASDAQ:...

Biofrontera is eyeing significant growth opportunities for its FDA-approved skin disease photodynamic therapy drug "Ameluz". Updates regarding several ongoing clinical studies for expanded label indications can be a catalyst for the stock in 2022. While Biofrontera maintains a pos...

The following slide deck was published by Biofrontera AG in conjunction with this event. For further details see: Biofrontera (BFRA) Investor Presentation - Slideshow

Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...

Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals NRXP +48% after Zyesami increased likel...

Gainers: Biofrontera (NASDAQ:BFRI) +154%. Longeveron (NASDAQ:LGVN) +79%. Ocuphire Pharma (NASDAQ:OCUP) +36%. Society Pass (NASDAQ:SOPA) +24%. Biofrontera (NASDAQ:BFRA) +23%. Better Therapeutics (NASDAQ:BTTX) +20%. Applied UV (NASDAQ:AUVI) +19%. Standard Lithium (NYSE:SLI) +19%. Blue Star Food...

Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal ...